Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized
By
Anna Eramo
Christoph U. Correll
David P. Walling
Rishi Kakar
Niccolo Bassani
Leslie Callahan
Baker P. Lee
Zachary Prensky
Andrew R. Vaino
John M. Kane
July 1, 2026
Clinical Scorecard: Efficacy and Safety Profile of LB-102 as an Antipsychotic for Adults Experiencing Acute Schizophrenia: A Randomized Study
At a Glance
Category Detail
Condition Acute Schizophrenia Key Mechanisms High-affinity antagonism at D2/D3 and serotonin (5-HT7) receptors with improved blood-brain barrier penetration. Target Population Adults aged 18-55 years with a primary diagnosis of schizophrenia. Care Setting Inpatient clinical trial settings.
Key Highlights
LB-102 demonstrates sustained D2/D3 blockade with once-daily dosing. Phase 1 trial shows rapid absorption and linear pharmacokinetics. LB-102 achieves therapeutic receptor occupancy at lower systemic exposures compared to amisulpride. The trial is a double-blind, placebo-controlled study conducted at 25 sites in the US. Participants required hospitalization for acute exacerbation of psychotic symptoms. Guideline-Based Recommendations
Diagnosis
Confirmed primary diagnosis of schizophrenia using the Mini-International Neuropsychiatric Interview (MINI). Management
Randomized to receive LB-102 or placebo for treatment of acute schizophrenia. Monitoring & Follow-up
Monitor for adverse effects including transient prolactin elevation and extrapyramidal symptoms. Risks
Potential for QTc prolongation and hyperprolactinemia with higher doses. Patient & Prescribing Data
Adults aged 18-55 years experiencing acute exacerbation of schizophrenia.
LB-102 provides potential benefits over traditional antipsychotics with improved tolerability.
Clinical Best Practices
Ensure participants are free from antipsychotic treatment for 2 weeks prior to baseline assessment. Conduct thorough screening to confirm diagnosis and assess symptom severity. Related Resources & Content
